Martine A. Rothblatt Sells 1,265 Shares of United Therapeutics Corporation (UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,265 shares of United Therapeutics Corporation stock in a transaction on Thursday, October 19th. The shares were sold at an average price of $119.38, for a total value of $151,015.70. Following the completion of the sale, the chief executive officer now directly owns 1,405 shares of the company’s stock, valued at approximately $167,728.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 121.01 on Friday. The stock has a market cap of $5.26 billion, a P/E ratio of 14.03 and a beta of 1.49. The firm’s 50-day moving average price is $121.87 and its 200-day moving average price is $125.73. United Therapeutics Corporation has a 52-week low of $111.11 and a 52-week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. During the same quarter in the prior year, the business posted $4.42 earnings per share. United Therapeutics Corporation’s revenue was up 7.8% on a year-over-year basis. On average, equities research analysts forecast that United Therapeutics Corporation will post $10.60 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first posted by Week Herald and is owned by of Week Herald. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://weekherald.com/2017/10/22/martine-a-rothblatt-sells-1265-shares-of-united-therapeutics-corporation-uthr-stock.html.

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of United Therapeutics Corporation by 3.3% during the second quarter. BlackRock Inc. now owns 4,897,334 shares of the biotechnology company’s stock worth $635,330,000 after acquiring an additional 155,349 shares in the last quarter. FMR LLC raised its holdings in shares of United Therapeutics Corporation by 2.8% during the second quarter. FMR LLC now owns 4,254,841 shares of the biotechnology company’s stock worth $551,980,000 after acquiring an additional 116,062 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of United Therapeutics Corporation by 0.7% during the second quarter. Vanguard Group Inc. now owns 3,810,146 shares of the biotechnology company’s stock worth $494,291,000 after acquiring an additional 25,047 shares in the last quarter. State Street Corp raised its holdings in shares of United Therapeutics Corporation by 0.9% during the second quarter. State Street Corp now owns 2,014,506 shares of the biotechnology company’s stock worth $261,345,000 after acquiring an additional 17,179 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of United Therapeutics Corporation by 5.3% during the second quarter. Acadian Asset Management LLC now owns 1,142,056 shares of the biotechnology company’s stock worth $148,160,000 after acquiring an additional 57,509 shares in the last quarter.

A number of equities research analysts have recently commented on UTHR shares. ValuEngine raised United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a research report on Friday, September 8th. TheStreet downgraded United Therapeutics Corporation from a “b-” rating to a “c” rating in a research report on Friday, September 29th. Zacks Investment Research raised United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a research report on Monday, October 9th. Finally, BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Five analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $132.09.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply